OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy
Hisamitsu Ishihara, Susumu Yamaguchi, Toshifumi Sugitani, et al.
Clinical Drug Investigation (2019) Vol. 39, Iss. 12, pp. 1213-1221
Open Access | Times Cited: 5
Hisamitsu Ishihara, Susumu Yamaguchi, Toshifumi Sugitani, et al.
Clinical Drug Investigation (2019) Vol. 39, Iss. 12, pp. 1213-1221
Open Access | Times Cited: 5
Showing 5 citing articles:
Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 10, pp. 2284-2293
Open Access | Times Cited: 38
Kohei Kaku, Hiroyuki Isaka, Taishi Sakatani, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 10, pp. 2284-2293
Open Access | Times Cited: 38
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV
Samuel Dagogo‐Jack, Robert Frederich, Jie Liu, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 8, pp. 2042-2051
Open Access | Times Cited: 5
Samuel Dagogo‐Jack, Robert Frederich, Jie Liu, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 8, pp. 2042-2051
Open Access | Times Cited: 5
Sodium–glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism
Wataru Ogawa, Yushi Hirota
Journal of Diabetes Investigation (2019) Vol. 10, Iss. 4, pp. 879-882
Open Access | Times Cited: 9
Wataru Ogawa, Yushi Hirota
Journal of Diabetes Investigation (2019) Vol. 10, Iss. 4, pp. 879-882
Open Access | Times Cited: 9
A Scoping Review Evaluating the Effect of SGLT-2 Inhibitors on Insulin Dose Requirements in Insulin-Dependent Patients With Type 2 Diabetes
Morgan K. Moulton, Blake R. Johnson, Devin L. Lavender, et al.
Annals of Pharmacotherapy (2022) Vol. 56, Iss. 9, pp. 1030-1040
Closed Access | Times Cited: 5
Morgan K. Moulton, Blake R. Johnson, Devin L. Lavender, et al.
Annals of Pharmacotherapy (2022) Vol. 56, Iss. 9, pp. 1030-1040
Closed Access | Times Cited: 5
SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice
Atsuo Tahara
European Journal of Pharmacology (2021) Vol. 910, pp. 174486-174486
Closed Access | Times Cited: 2
Atsuo Tahara
European Journal of Pharmacology (2021) Vol. 910, pp. 174486-174486
Closed Access | Times Cited: 2
